Mirvetuximab soravtansine
- Generic Name
- Mirvetuximab soravtansine
- Brand Names
- Elahere
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1453084-37-1
- Unique Ingredient Identifier
- 98DE7VN88D
- Background
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.
...
- Indication
Mirvetuximab soravtansine is indicated for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
...
- Associated Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Platinum Resistant Primary Peritoneal Cancer, Platinum drug resistant Fallopian tube cancer
- Associated Therapies
- -
Cancer Antibody Drug Conjugates Market, Drugs Approval, Price, Sales & Clinical Trials
Antibody drug conjugates (ADCs) are a transformative class in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is expected to surpass $50B by 2030, driven by over 500 ADCs in clinical trials. Key players include Enhertu, Kadcyla, and Padcev, with significant sales in breast and lung cancers. The US and China lead the market, supported by robust R&D and regulatory environments.
ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Platinum-Resistant Ovarian Cancer
Platinum-resistant ovarian cancer's treatment challenge is addressed by the development of the oral, selective GR modulator relacorilant, which aims to block cortisol's antiapoptotic effects in GR-overexpressing solid tumors. The phase 3 ROSELLA study is underway to confirm relacorilant's efficacy with nab-paclitaxel in platinum-resistant ovarian cancer, based on promising phase 2 data showing improved progression-free survival and duration of response.
Related Clinical Trials:
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024
The Cancer Antibody Drug Conjugates Market report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is projected to surpass $50B by 2030, driven by ongoing clinical trials and increased R&D efforts. Key players include Padcev, Kadcyla, and Enhertu, with significant development activity in lung and breast cancer. The market is led by the US and China, with major pharmaceutical companies driving innovation.
Evolving FDA Accelerated Approval Pathway Suffers Spate of Withdrawals
Pfizer's sickle cell disease therapy Oxbryta was pulled from market due to risks, highlighting the challenges of accelerated approval. The FDA's program has brought nearly 300 drugs to market, often years earlier, but success rates vary. While many drugs have secured traditional approval, others like Oxbryta and Aduhelm were ultimately unsuccessful. The pathway relies on biomarkers predicting clinical benefit, but confirmatory trials are often delayed, raising concerns about safety and efficacy. Experts argue for tighter deadlines and better validation of biomarkers to improve the program's reliability.
Global Cancer Antibody Drug Conjugates Market Size Forecast 2030
The global cancer antibody drug conjugates (ADCs) market is projected to exceed $50 billion by 2030, driven by 16 approved drugs and over 500 in clinical trials. ADCs, combining chemotherapy's cytotoxic effects with monoclonal antibodies' specificity, minimize side effects and improve efficacy, particularly in solid tumors and hematological malignancies. The market, valued at $10 billion in 2023, is expected to surpass $13 billion in 2024, fueled by strategic alliances, significant investments, and advancements in antibody engineering and linker technology.
New cancer drug tied to vision loss, study suggests
A study found over 55% of Elahere users experienced vision loss due to corneal toxicity, with 69% showing signs of toxicity. Vision improved in 65% of eyes, and corneal toxicity significantly improved in almost all cases with corticosteroids and dosage adjustments.
Mirvetuximab Soravtansine Effective in Patients With FRα+, Platinum-Sensitive Ovarian Cancer
Mirvetuximab soravtansine (Elahere; AbbVie) demonstrated efficacy and tolerability in heavily pretreated patients with folate receptor alpha-positive, platinum-sensitive ovarian cancer (PSOC) in the phase 2 PICCOLO trial, with an objective response rate of 51.9%.
Related Clinical Trials:
Elahere: Side effects and how to manage them
Elahere can cause temporary mild side effects like abdominal pain, blurred vision, and fatigue, and serious side effects including ascites, intestinal blockage, and severe liver function changes. It may also cause long-term side effects such as eye problems and peripheral neuropathy. If side effects persist or worsen, consult a doctor. Elahere has a boxed warning for serious eye problems, requiring regular eye exams and potential dosage adjustments.
Immunoglobulin Market Size to Worth around USD 28.70 Bn by 2034
The immunoglobulin market, valued at US$ 13.36 billion in 2023, is projected to reach US$ 28.70 billion by 2034, driven by its use in treating immunodeficiency and other applications. Key growth factors include immunodeficiency disorders, infections, and thrombocytopenia. North America leads with a 46% share, while Asia-Pacific is expected to grow fastest due to increased health spending and prevalence of autoimmune diseases. Recent advancements include subcutaneous injection therapies and acquisitions by major pharmaceutical companies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath